Prostate tumor growth and recurrence can be modulated by the ω-6:ω-3 ratio in diet: Athymic mouse xenograft model simulating radical prostatectomy

Neoplasia

Volumn 8, Issue 2, 2006, Pages 112-124

  Kelavkar, Uddhav P ^a,c   Hutzley, Justin ^a   Dhir, Rajiv ^a   Kim, Paul ^b   Allen, Kenneth G D ^b   McHugh, Kevin ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

15 lipoxygenase 1; Cancer prevention; Polyunsaturated fatty acids; Prostate cancer; Radical prostatectomy

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; FATTY ACID ESTER; FISH OIL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTATE SPECIFIC ANTIGEN; STEARIDONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DIETARY INTAKE; ENZYME METABOLISM; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FOOD INTAKE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 33645894682     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05637     Document Type: Article

References (87)

1. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, et al. (2004). Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64, 2270-2305.
2. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, et al. (1977). Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20, 680-688.
3. Dunn JE (1975). Cancer epidemiology in populations of the United States - with emphasis on Hawaii and California - and Japan. Cancer Res 35, 3240-3245.
4. Haenszel W and Kurihara M (1968). Studies of Japanese migrants: I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40, 43-68.
5. Shennen DH and Bishop OS (1974). Diet and mortality from malignant disease in 32 countries. West Indian Med J 23, 44.
6. Blair A and Fraumeni JF (1978). Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst 61, 1379-1384.
7. Armstrong B and Doll R (1975). Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15, 617-631.
8. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D, and Aronson WJ (2003). Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res 9, 2734-2743.
9. Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, Freedland SJ, and Aronson WJ (2004). Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Res 64, 1252-1254.
10. Kang JX, Wang J, Wu L, and Kang ZB (2004). Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 427, 504.
11. Crawford MA (1992). The role of dietary fatty acids in biology: their place in the evolution of the human brain. Nutr Rev 50, 3-11.
12. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, and Jackson RT (1999). Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 81, 1238-1242.
13. Emken EA, Adlof RO, and Gulley RM (1994). Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and ALAs in young adult males. Biochim Biophys Acta 1213, 277-288.
14. Willett WC (1997). Specific fatty acids and risks of breast and prostate cancer: dietary intake. Am J Clin Nutr 66, 1557S-1563S.
15. Iynem AH, Alademir AZ, Obek C, Kural AR, Konukoglu D, and Akcay T (2004). The effect of prostate cancer and antiandrogenic therapy on lipid peroxidation and antioxidant systems. Int Urol Nephrol 36, 57-62.
16. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, and Mukhtar H (2001). Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91, 737-743.
17. Kelavkar UP, Cohen C, Kamitani H, Eling TE, and Badr KF (2000). Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 10, 1777-1787.
18. Kelavkar U, Glasgow W, and Eling T (2002). The effect of 15-lipoxygenase-1 (15-LO-1) expression on cancer cells. Curr Urol Rep 3, 207-214.
19. Donaldson MS (2004). Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr J 3, 19-27.
20. Fukatsu T, et al. (2004). Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24, 2431-2437.
21. Kasper S (2005). Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 94, 279-297.
22. Kelavkar U, Nixon J, Cohen C, Dillehay D, Eling T, and Badr K (2001). Overexpression of 15-lipoxygenase-1 (15-LO-1) in PC-3 human prostate cancer cells causes aggressive tumorigenesis. Carcinogenesis 22, 1765-1773.
23. Kelavkar UP and Cohen C (2004). 15-Lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia 6, 41-52.
24. Kamitani H, Geller M, and Eling T (1998). Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 273, 21569-21577.
25. Glasgow WC, Afshari CA, Barrett JC, and Eling TE (1992). Modulation of the epidermal growth factor mitogenic response by metabolites of linoleic and arachidonic acid in Syrian hamster embryo fibroblasts. Differential effects in tumor suppressor gene (+) and (-) phenotypes. J Biol Chem 267, 10771-10779.
26. Sauer LA, Dauchy RT, Blask DE, Armstrong BJ, and Scalici S (1999). 13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic acid-dependent growth in rat hepatoma 7288CTC in vivo vivo. Cancer Res 59, 4688-4692.
27. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, and Kopff HS (1999). Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 59, 4693-4701.
28. Blask DE, Dauchy RT, Sauer LA, and Krause JA (2004). Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 25, 951-960.
29. Coleman KE, Kelavkar UP, Lawson D, Haseman J, and Cohen C (2002). 15-Lipoxygenase-1 (15-LO-1) as a molecular marker in cancer: an immunohistochemical study. Mod Pathol 15, 304A.
30. Shureiqi I, et al. (1999). Decreased 13- S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20, 1985-1995.
31. Hsi LC, Xi X, Lotan R, Shureiqi I, and Lippman SM (2004). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res 64, 8778-8781.
32. Kelavkar UP, Glasgow W, Olson SJ, Foster BA, and Shappell SB (2004). Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 6, 821-830.
33. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken JD, Barrios RS, and Greenberg NM (2000). E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60, 2203-2208.
34. Brash AR (1999). Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274, 23679-23682.
35. Wang W, Bergh A, and Damber JE (2005). Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11, 3250-3256.
36. O'Neill GP and Ford-Hutchinson AW (1993). Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330, 156-160.
37. Hussain T, Gupta S, and Mukhtar H (2003). Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191, 125-135.
38. Narayanan NK, Narayanan BA, and Reddy BS (2005). A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int J Oncol 26, 785-792.
39. Hughes-Fulford M, Chen Y, and Tjandrawinata RR (2001). Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 22, 701-707.
40. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, and Reddy ST (2003). Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 100, 1751-1756.
41. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, and Gronert K (2000). Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids matory via cyclooxygenase 2 nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192, 1197-1204.
42. Andersson A, Sjödin A, Hedman A, Olsson R, and Vessby B (2000). Fatty acid profile of skeletal muscle phospholipids in trained and untrained young men. Am J Physiol Endocrinol Metab 279, E744-E751.
43. Ursin VM (2003). Modification of plant lipids for human health: development of functional land-based omega-3 fatty acids. J Nutr 133, 4271-4274.
44. Hem A, Smith AJ, and Solberg P (1998). Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink. Lab Anim 32, 364-368.
45. Balas J, Pawlicka M, Jacorzynski B, Filipek A, Domina P, Mielniczuk E, and Daniewski M (2001). The fat and fatty acids content in selected sea fish. Rocz Panstw Zakl Hig 52, 277-284.
46. Richardson AJ, Easton T, and Puri BK (2000). Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Eur Neuropsychopharmacol 10, 189-193.
47. Farquhar JW and Ahrens EH (1963). Effects of dietary fats on human erythrocyte fatty acid patterns. J Clin Invest 42, 675-685.
48. Yamori Y, Nara Y, Iritani N, Workman RJ, and Inagami T (1985). Comparison of serum phospholipid fatty acids among fishing and farming Japanese populations and American inlanders. J Nutr Sci Vitaminol (Tokyo) 31, 417-422.
49. Dyerberg J, Bang HO, and Hjome N (1975). Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 28, 958-966.
50. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, and Ma J (2002). Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346, 1113-1118.
51. Shepherd IL (2002). Resistance to changes in diet. Proc Nutr Soc 61, 267-272.
52. Farquhar JW and Ahrens EH (1963). Effects of dietary fats on human erythrocyte fatty acid patterns. J Clin Invest 42, 675-685.
53. Lee MM, Chang JS, Jacobs B, and Wrensch MR (2002). Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am J Public Health 92, 1606-1609.
54. Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM, and Wootton J (1999). Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27, 623-630.
55. Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, and Bowen DJ (2003). Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103, 323-328.
56. Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, and Slevin ML (1994). Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309, 86-89.
57. Wynder EL, Mabuchi K, Whitmore WF Jr (1971). Epidemiology of cancer of the prostate. Cancer 28, 344-360.
58. Terry P, Lichtenstein P, Feychting M, Ahlbom A, and Wolk A (2001). Fatty fish consumption and risk of prostate cancer. Lancet 357, 1764-1766.
59. Terry PD, Rohan TE, and Wolk A (2003). Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 77, 532-543.
60. Yang YJ, Lee S Ho, Hong SJ, and Chung BC (1999). Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 32, 405-409.
61. Freeman VL, Meydani M, Yong S, Pyle J, Flanigan RC, Waters WB, and Wojcik EM (2000). Prostatic levels of fatty acids and the histopathology of localized prostate cancer. J Urol 164, 2168-2172.
62. Freeman VL, Meydani M, Hur K, and Flanigan RC (2004). Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Cancer 101, 2744-2754.
63. Pandalai PK, Pilat MJ, Yamazaki K, Naik H, and Pienta KJ (1996). The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res 16, 815-820.
64. Fleshner N, Bagnell PS, Klotz L, and Venkateswaran V (2004). Dietary fat and prostate cancer. J Urol 171, S19-S24.
65. Tang S, et al. (2002). Evidence that arachidonate 15-lipoxygenase 2 is a negative cell-cycle regulator in normal prostate epithelial cells. J Biol Chem 277, 16189-16201.
66. Coutant F, Agaugue S, Perrin-Cocon L, Andre P, and Lotteau V (2004). Sensing environmental lipids by dendritic cell modulates its function. J Immunol 172, 54-60.
67. Serhan CN, et al. (2003). Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 171, 6856-6865.
68. Nelson WG, De Marzo AM, DeWeese TL, and Isaacs WB (2004). The role of inflammation in the pathogenesis of prostate cancer. J Urol 172, S6-S11.
69. Donnell RF (2004). Epidemiology of inflammation and prostate cancer. Curr Urol Rep 5, 297.
70. Shappell SB, Boeglin WE, Olson SJ, Kasper S, and Brash AR (1999). 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155, 235-245.
71. Simopoulos AP, Leaf A, and Salem N (1999). Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab 43, 127-130.
72. Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, and Etherton TD (2000). Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr Suppl 71, 179S-188S.
73. Jonnalagadda SS, Egan SK, Heimbach JT, Harris SS, and Kris-Etherton PM (1995). Fatty acid consumption patterns of Americans: 1987-1988 USDA Nationwide Food Consumption Survey. Nutr Res 15, 1767-1781.
74. Allison DB, Egan SK, Barraj LM, Caughman C, Infante M, and Heimbach JT (1999). Estimated intake of trans fatty acids and other fatty acids in the US population. J Am Diet Assoc 99, 166-174.
75. Knapp HR, Reilly IA, Alessandrini P, and FitzGerald GA (1986). In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 314, 937-942.
76. Knapp HR and FitzGerald GA (1989). The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 320, 1037-1043.
77. Ip C (1997). Review of the effects of trans fatty acids, oleic acid, n-3 polyunsaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals. Am J Clin Nutr 66, 1523-1529.
78. Hrelia S, Bordoni A, Celadon M, Turchetto E, Biagi PL, and Rossi CA (1989). Age-related changes in linoleate and alpha-linoleate desaturation by rat liver microsomes. Biochem Biophys Res Commun 163, 348-355.
79. Newcomer LM, King IB, Wicklund KG, and Stanford JL (2001). The association of fatty acids with prostate cancer risk. Prostate 47, 262-268.
80. De Stefani E, Deneo-Pellegrini H, Boffetta P, Ronco A, and Mendilaharsu M (2000). Alphalinolenic acid and risk of prostate cancer: a case-control study in Uruguay. Cancer Epidemiol Biomark Prev 9, 335-338.
81. Blot WJ, Lanier A, Fraumeni JF, and Bender TR (1975). Cancer mortality among Alaska natives, 1960-1969. J Natl Cancer Inst 55, 546-554.
82. Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, and Vatten L (1997). Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 71, 545-551.
83. Chung BH, Mitchell SH, Zhang JS, and Young CYF (2001). Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 22, 1201-1206.
84. Rose DP (1996). The mechanistic rationale in support of dietary cancer prevention. Prev Med 25, 34-37.
85. Kaplan PJ, Mohan S, Cohen P, Foster BA, and Greenberg NM (1999). The insulin-like growth factor axis and prostate cancer: lessons from the TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) model. Cancer Res 59, 2203-2209.
86. Nelson JB and Lepor H (2003). Prostate cancer: radical prostatectomy. Urol Clin North Am 30, 703-723 (viii).
87. Ward JF, Blute ML, Slezak J, Bergstralh EJ, and Zincke H (2003). The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170, 1872-1876.